دورية أكاديمية
Antiinflammatory therapy with canakinumab for atherosclerotic disease
| العنوان: | Antiinflammatory therapy with canakinumab for atherosclerotic disease |
|---|---|
| المؤلفون: | PM Ridker, BM Everett, T Thuren, JG MacFadyen, WH Chang, C Ballantyne, F Fonseca, J Nicolau, W Koenig, SD Anker, JJP Kastelein, JH Cornel, P Pais, D Pella, J Genest, R Cifkova, A Lorenzatti, T Forster, Z Kobalava, L Vida-Simiti, M Flather, H Shimokawa, H Ogawa, M Dellborg, PRF Rossi, RPT Troquay, P Libby, RJ Glynn, H Krum, J Varigos, P Siostrzonek, P Sinnaeve, N Gotcheva, H Yong, M Urina-Triana, D Milicic, R Vettus, AJ Manolis, F Wyss, A Sigurdsson, A Fucili, I Veze, B Petrauskiene, L Salvador, TO Klemsdal, F Medina, A Budaj, P Otasevic, M Lainscak, KB Seung, P Commerford, M Donath, JJ Hwang, H Kultursay, S Bilazarian, C East, L Forgosh, B Harris, M Ligueros, E Bohula, B Charmarthi, S Cheng, S Chou, J Danik, G McMahon, B Maron, M Ning, B Olenchock, R Pande, T Perlstein, A Pradhan, N Rost, A Singhal, V Taqueti, N Wei, H Burris, A Cioffi, AM Dalseg, N Ghosh, J Gralow, T Mayer, H Rugo, V Fowler, AP Limaye, S Cosgrove, D Levine, R Lopes, J Scott, R Hilkert, G Tamesby, C Mickel, B Manning, J Woelcke, M Tan, S Manfreda, T Ponce, J Kam, R Saini, K Banker, T Salko |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Science & Technology, Life Sciences & Biomedicine, Medicine, General & Internal, General & Internal Medicine, C-REACTIVE PROTEIN, CORONARY-ARTERY-DISEASE, CARDIOVASCULAR-DISEASE, STATIN THERAPY, INTERLEUKIN-1-BETA INHIBITION, MYOCARDIAL-INFARCTION, CLONAL HEMATOPOIESIS, HEART-DISEASE, INFLAMMATION, RISK, canakinumab, antiinflammatory therapy, atherosclerotic disease, atherothrombosis, myocardial infarction, 110999 Neurosciences not elsewhere classified, 920410 Mental Health, Faculty of Health, School of Medicine, Institute for Innovation in Mental and Physical Health and Clinical Translation, 3209 Neurosciences, 3201 Cardiovascular medicine and haematology, 3202 Clinical sciences, 420313 Mental health services, 200409 Mental health |
| الوصف: | BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. METHODS: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P=0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P=0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P=0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P=0.005). Canakinumab ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| العلاقة: | http://hdl.handle.net/10779/DRO/DU:20792194.v2Test; https://figshare.com/articles/journal_contribution/Antiinflammatory_therapy_with_canakinumab_for_atherosclerotic_disease/20792194Test |
| الإتاحة: | http://hdl.handle.net/10779/DRO/DU:20792194.v2Test https://figshare.com/articles/journal_contribution/Antiinflammatory_therapy_with_canakinumab_for_atherosclerotic_disease/20792194Test |
| حقوق: | All Rights Reserved |
| رقم الانضمام: | edsbas.E283BB54 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |